

Cholangiocarcinoma Reference Handout

Cholangiocarcinoma Dx

Bile Duct Epithelial Cells

Cholangiocarcinoma can occur

- 1) INTRA- hepatic
- 2) EXTRA- hepatic
- 3) Gallbladder
- 4) Perihilar

Work Up

Multiphasic MRI/CT
CT Chest

+/- MRCP or EUS

Labs: CEA, CA19-9, AFP

Staging

T1

T0 = carcinoma in situ

T1 = submucosa

T2 = muscularis propria

T3 = serosa

T4 = major blood vessels: portal vein or hepatic artery, extra-hepatic structures

N

N1 = 1-3 LN (includes "tumor deposits")

N2 = 4+ LN

M

M1 = distant mets, includes peritoneum

Stage

Stage I-II = T1-2N0

Stage III = T3N0 or T1-3N1

Stage IV = T4 or N2

Cholangiocarcinoma Early Stage Tx

Resectable

Surgery

T0-T1

= cholecystectomy/partial hepatectomy

T2+

= en bloc resection of gallbladder/liver

+ bile duct excision

+ LND

Adjuvant Therapy or Unresectable

1. Observe if: < T2, N0, R0

2. Adjuvant if: > T2, N+, R+

Chemo

ChemoRT

Clinical Trial

Options for Chemo/ChemoRT

Capecitabine +/- Gemcitabine

5FU

Cholangiocarcinoma Metastatic Tx

Front Line

Gemcitabine/Cisplatin

+/- Durvalumab or Pembrolizumab

Second Line

5FU or Gemcitabine-based chemo

FOLFOX/FOLFIRI

GEMOX

CAPOX

Pembrolizumab + Lenvatinib

Targeted Therapy for Special Populations

FGFR2

Futibatinib

Pemigatinib

MSI-High/dMMR

Pembrolizumab

IDH1

Ivosidenib

BRAF V600E

Dabrafenib/Trametinib

NTRK

Entrectinib

Larotrectinib

HER2

Trastuzumab/Pertuzumab

Zanidatamab no FDA approval yet